Select Page
Recommendations for unleashing meaningful innovation through regulatory reform

Recommendations for unleashing meaningful innovation through regulatory reform

What do we know when a new medicine is approved? What are the regulatory requirements for new medicines? What happens once a new drug is on the market? Following the first  of the EPHA #A2MDialogues,  our panelists Andrea Cipriani, Lydia Meheus, Huseyin Naci and Beate...
Public health must be the leading priority of Europe’s pharmaceutical sector

Public health must be the leading priority of Europe’s pharmaceutical sector

The EU must ensure access to affordable and quality medicines in Europe whilst guaranteeing everyone’s right to a healthy and sustainable environment. Human medicine is not an ordinary commodity – public interest and public health should prevail as leading...
Patients can’t wait any longer for action on medicine shortages

Patients can’t wait any longer for action on medicine shortages

DOWNLOAD THE PAPER DOWNLOAD THE PR The increasing levels of medicine shortages across Europe pose severe threats to patient outcomes, patient safety and the patient care continuum. The European Public Health Alliance (EPHA) calls for an urgent resolution of the...
Getting it right: EPHA recommendations on how to improve the European Commission proposal on Health Technology Assessment (HTA)

Getting it right: EPHA recommendations on how to improve the European Commission proposal on Health Technology Assessment (HTA)

EPHA welcomes the European Commission proposal for a Regulation on Health Technology Assessment (HTA), amending Directive 2011/24/EU. We believe strongly in Health Technology Assessment as  a powerful ally of patients and healthcare systems. Our recommendations aim to...